| 臺大學術典藏 |
2020-03-27T05:28:50Z |
Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections
|
Huang C.-H.; Ko W.-C.; Chen Y.-H.; PO-REN HSUEH; Lin S.-Y.; PO-REN HSUEH;Chen Y.-H.;Ko W.-C.;Huang C.-H.;Lin S.-Y. |
| 臺大學術典藏 |
2020-03-27T05:28:49Z |
Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters
|
Ko W.-C.;Lee N.-Y.;Chang C.-M.;Li M.-J.;Li C.-W.;Lee C.-C.;PO-REN HSUEH;Cheng W.-L.; Cheng W.-L.; PO-REN HSUEH; Lee C.-C.; Li C.-W.; Li M.-J.; Chang C.-M.; Lee N.-Y.; Ko W.-C. |
| 臺大學術典藏 |
2020-03-27T05:28:47Z |
RNA polymerase B subunit gene mutations in?biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment
|
Chuang Y.-C.; Ko W.-C.; Toh H.-S.; Chiang S.-R.; Yu W.-L.; Chiu Y.-H.; Weng T.-C.; Zhang C.-C.; Wu K.-Y.; Lin Y.-C.; PO-REN HSUEH; Chen C.-C.; Tang H.-J.; Lai C.-C.; Chuang Y.-C.;Ko W.-C.;Yu W.-L.;Chiang S.-R.;Toh H.-S.;Chiu Y.-H.;Weng T.-C.;Zhang C.-C.;Lin Y.-C.;Wu K.-Y.;Chen C.-C.;PO-REN HSUEH;Lai C.-C.;Tang H.-J. |
| 臺大學術典藏 |
2020-03-27T05:28:43Z |
Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
|
PO-REN HSUEH;Liu C.-Y.;Lam C.;Lu M.-C.;Liu J.-W.;Chen Y.-S.;Chen Y.-H.;Wu J.-J.;Chen R.-J.;Ko W.-C.;Chang F.-Y.;Hsu C.-W.;Liao C.-H.;Yu K.-W.;Lee W.-S.;Jean S.-S.; Jean S.-S.; Lee W.-S.; Yu K.-W.; Liao C.-H.; Hsu C.-W.; Chang F.-Y.; Ko W.-C.; Chen R.-J.; Wu J.-J.; Chen Y.-H.; Chen Y.-S.; Liu J.-W.; Lu M.-C.; Lam C.; Liu C.-Y.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:41Z |
Corrigendum to “Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009” [Diagn Microbiol Infect Dis 2015;81(4):290–295] (S0732889314004076)(10.1016/j.diagmicrobio.2014.09.027)
|
PO-REN HSUEH;Chen R.-J.;Liu C.-Y.;Lu M.-C.;Liu J.-W.;Chen Y.-S.;Chen Y.-H.;Wu J.-J.;Ko W.-C.;Chang F.-Y.;Liao C.-H.;Hsu C.-W.;Yu K.-W.;Bai K.-J.;Lee W.-S.;Jean S.-S.; Jean S.-S.; Lee W.-S.; Bai K.-J.; Yu K.-W.; Hsu C.-W.; Liao C.-H.; Chang F.-Y.; Ko W.-C.; Wu J.-J.; Chen Y.-H.; Chen Y.-S.; Liu J.-W.; Lu M.-C.; Liu C.-Y.; Chen R.-J.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:40Z |
Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan
|
PO-REN HSUEH;Tseng S.-H.;Ko W.-C.;Lo Y.-T.;Jan Y.-N.;Kang M.-Y.;Tsai T.-L.;Wang L.-F.;Lu M.-C.;Chiang H.-T.;Lai C.-C.;Lee C.-M.; Lee C.-M.; Lai C.-C.; Chiang H.-T.; Lu M.-C.; Wang L.-F.; Tsai T.-L.; Kang M.-Y.; Jan Y.-N.; Lo Y.-T.; Ko W.-C.; Tseng S.-H.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:40Z |
Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
|
Ko W.-C.;Lee N.-Y.;PO-REN HSUEH;Li M.-C.;Li C.-W.;Lee C.-C.;Lo C.-L.; Lo C.-L.; Lee C.-C.; Li C.-W.; Li M.-C.; PO-REN HSUEH; Lee N.-Y.; Ko W.-C. |
| 臺大學術典藏 |
2020-03-27T05:28:39Z |
Implementation of a national bundle care program to reduce catheter-associated urinary tract infection in high-risk units of hospitals in Taiwan
|
for the, Infection Control Society of Taiwan;PO-REN HSUEH;Chen Y.-H.;Tseng S.-H.;Ko W.-C.;Chuang Y.-C.;Lu M.-C.;Liu C.-P.;Liu J.-W.;Shi Z.-Y.;Su L.-H.;Chen Y.-C.;Hung C.-T.;Chiang H.-T.;Lee C.-M.;Lai C.-C.; Lai C.-C.; Lee C.-M.; Chiang H.-T.; Hung C.-T.; Chen Y.-C.; Su L.-H.; Shi Z.-Y.; Liu J.-W.; Liu C.-P.; Lu M.-C.; Chuang Y.-C.; Ko W.-C.; Tseng S.-H.; Chen Y.-H.; PO-REN HSUEH; for the, Infection Control Society of Taiwan |
| 臺大學術典藏 |
2020-03-27T05:28:37Z |
Role of rifampin for the treatment of bacterial infections other than mycobacteriosis
|
PO-REN HSUEH;Chen Y.-H.;Ko W.-C.;Lu P.-L.;Huang C.-H.;Lee C.-Y.; Lee C.-Y.; Huang C.-H.; Lu P.-L.; Ko W.-C.; Chen Y.-H.; PO-REN HSUEH |
| 臺大學術典藏 |
2020-03-27T05:28:35Z |
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: Results from the 2017 surveillance of multicenter antimicrobial resistance in Taiwan (SMART)
|
PO-REN HSUEH;Wang F.-D.;Ko W.-C.;Shao P.-L.;Lu P.-L.;Wu T.-S.;Tseng S.-H.;Shi Z.-Y.;Lu M.-C.;Jean S.-S.; Jean S.-S.; Lu M.-C.; Shi Z.-Y.; Tseng S.-H.; Wu T.-S.; Lu P.-L.; Shao P.-L.; Ko W.-C.; Wang F.-D.; PO-REN HSUEH |
